PROFYLE

Thank you for completing our survey

Thank you for taking the time to complete our supporter survey, your thoughts and opinions are very important to us. In your response you indicated an interest in learning more about PROFYLE (PRecision Oncology For Young peopLE) an exciting new initiative to treat the rarest childhood and young adult cancers.

If you are ready to sign on with your support right away and start changing lives, or if you have any questions after reading the information provided below, please do not hesitate to reach out directly to Derek Yarnell (dyarnell@cancercare.mb.ca) who will be happy to help you.

Thank you so very much for your consideration of an investment in this leading-edge partnership.


When a family is told their child or adolescent has cancer, their world crashes. Learning the current five year survival rate is 80 per cent provides some comfort, however the fear and anxiety of being one of the 20 per cent of patients is unfathomable.

First time in Canadian history

For the first time in Canadian history, more than 30 pediatric cancer research and funding organizations, including CancerCare Manitoba and the Foundation – along with thousands of individual and corporate donors, have joined forces to give children, adolescents and young adults who have a very low survival rate over five years another chance to beat their cancer.

Through Terry Fox PROFYLE, a pan-Canadian project, top scientists and clinicians, research centres, cancer charities and hospital foundations across the country have come together with donors to create new hope for young people who need it the most.

Donors, doctors and researchers work together

Each cancer has a unique signature that makes it grow and for some that means their cancer will not respond to treatment. By supporting the molecular profiling of these patients’ tumours, donors can help doctors and scientists discover new treatments that target the patient’s specific cancer, no matter where they live in Canada.

“Investment in PROFYLE optimizes our donors’ generous support,” says Annitta Stenning, CEO of CancerCare Manitoba Foundation. “This national collaboration is incredibly important to CancerCare Manitoba’s ability to treat these young patients. We cannot do this alone in Manitoba and that’s why this initiative is so exciting and provides tremendous hope.”

PROFYLE is breaking down regional barriers and giving young people from Manitoba who need it the most, access to the BEST cancer care in Canada. For example, CancerCare Manitoba can enroll a child or young adult who is out of treatment options in the study by having their tumour sample sent to one of three profiling sites in Canada. A national tumour board discusses the results, and if the patient meets the criteria for a clinical trial suitable for their cancer, they will then be enrolled.

With PROFYLE Manitobans have the opportunity to be part of Canadian history and part of the generation that closes the remaining 20 per cent gap in fighting these rare, high-risk and hard to treat cancers in children and young adults. CancerCare Manitoba and CancerCare Manitoba Foundation are extremely proud to be part of this as research and funding partners and are confident the people of Manitoba will embrace the opportunity to make a tremendous difference for these patients.

Continued success requires continued support

Thanks to Manitobans from all walks of life who give very generously, CancerCare Manitoba Foundation will provide CancerCare Manitoba with up to $1 million dollars over the next five years in support of PROFYLE. In order to enroll 10 patients per year, the cost is $175,000 or $17,500 per patient:

  • $15,200 is allocated toward the cost of the individual molecular profiling
  • $1,800 is to support two research nurses who will be responsible for the coordination of an extensive patient consent process
  • $500 is provided to Diagnostic Services of Manitoba to perform the initial testing required for molecular profiling



Eight-year-old Marlow Ploughman is one of these children. When her late-stage rhabdomyosarcoma (muscle cancer) relapsed for the fourth time, doctors told Marlow’s parents there were no more conventional treatments left to try. The news was devastating – but then the Ontario family learned about PROFYLE.

PROFYLE is extremely important, because with children like Marlow we have very few options except the one conventional protocol that we’re given,” said Marlow’s mom, Tanya Boehm. “PROFYLE provides a key to unlock the door to perhaps more options — or at least provides us more time to wait for some more options to come.”

What could be more rewarding than knowing a patient who would not have previously survived gets to live a full life because of your support?




Or contact Derek Yarnell (dyarnell@cancercare.mb.ca) for further information on how your support can have the greatest impact.

d
c